Compare BATRA & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BATRA | IDYA |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.6B |
| IPO Year | 2023 | 2019 |
| Metric | BATRA | IDYA |
|---|---|---|
| Price | $54.10 | $37.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 16 |
| Target Price | ★ $60.00 | $52.86 |
| AVG Volume (30 Days) | 64.4K | ★ 663.8K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 26.00 | ★ 61.90 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $732,492,000.00 | $218,710,000.00 |
| Revenue This Year | $12.40 | N/A |
| Revenue Next Year | $8.54 | $201.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 10.52 | ★ 3024.43 |
| 52 Week Low | $41.50 | $24.24 |
| 52 Week High | $58.37 | $42.68 |
| Indicator | BATRA | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 43.87 | 43.85 |
| Support Level | $53.62 | $35.11 |
| Resistance Level | $56.09 | $37.82 |
| Average True Range (ATR) | 1.12 | 1.27 |
| MACD | -0.19 | -0.40 |
| Stochastic Oscillator | 18.67 | 3.63 |
Atlanta Braves Holdings Inc is a holding company. It operates through its wholly-owned subsidiary, which is the owner and operator of the Atlanta Braves Major League Baseball Club and the mixed-use real estate development, The Battery Atlanta, and is the operator of the Atlanta Braves Major League Baseball Club's stadium, Truist Park. The company predominantly derives revenue related to the Braves baseball franchise and Truist Park from ticket sales, concessions, local broadcasting rights, advertising sponsorships, suites and premium seat fees, retail and licensing revenue, shared MLB revenue streams, including national broadcasting rights and licensing, and other sources. The company's reportable segments include: Baseball which generates key revenue, and Mixed-Use Development.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.